{{Drugbox
| IUPAC_name = 
| image = Ritipenem.png
| width = 
| alt = 
| image2 = 
| width2 = 
| drug_name = 
| caption = 
<!--Clinical data-->
| tradename = 
| licence_EU = <!-- EMA requires brand name -->
| licence_US = <!-- FDA may use generic name -->
| DailyMedID = <!-- preference to licence_US -->
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = 
| dependency_liability = 
| routes_of_administration = 
<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 
<!--Identifiers-->
| CAS_number = 
| CAS_supplemental = 
| ATCvet = 
| ATC_prefix = <!-- 'none' if uncategorised -->
| ATC_suffix = 
| ATC_supplemental = 
| PubChem = 
| PubChemSubstance = 
| IUPHAR_ligand = 
| DrugBank = 
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = D4SL77931L
| ChEMBL = 70088
| ChemSpiderID      = 59074
<!--Chemical data-->
| chemical_formula =
| C=10 | H=12 | Ag= | As= | Au= | B= | Bi= | Br= | Cl= | Co= | F= | Fe= | Gd= | I= | K= | Mn=
| N=2 | Na=
| O=6 | P= | Pt=
| S=1 | Se= | Sr= | Tc=| charge = 
| molecular_weight = 288.3 g/mol
| SMILES = C[C@@H](O)[C@@H]1[C@H]2SC(=C(N2C1=O)C(=O)O)COC(=O)N
| StdInChI          = 1S/C10H12N2O6S/c1-3(13)5-7(14)12-6(9(15)16)4(19-8(5)12)2-18-10(11)17/h3,5,8,13H,2H2,1H3,(H2,11,17)(H,15,16)/t3-,5+,8-/m1/s1
| StdInChIKey       = IKQNRQOUOZJHTR-UWBRJAPDSA-N
| synonyms = 
| density = 
| melting_point = 
| melting_high = 
| melting_notes = 
| boiling_point = 
| boiling_notes = 
| solubility = 
| specific_rotation = 
| sec_combustion = 
}}


'''Ritipenem''' is a [[penem]] class [[antimicrobial]] agent. Ritipenem is manufactured by [[Tanabe Seiyaku]] in the ritipenem acoxil [[prodrug]] form, which can be taken orally . It is not FDA approved in the United States as of 2008.

==References==
* Eiland E, Gatlin D (2008). Forecast of Antimicrobial Development in an Era of Increasing Bacterial Resistance. ''Journal of Pharmacy Practice''. 21 (1): 313â€“18

{{Cell wall disruptive antibiotics}}





{{Antibiotic-stub}}
[[Category:Antibiotics]]